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received DBS for severe TS at St Andrews War Memorial Hospi-
tal, Brisbane, Australia from September 2008 to February 2012. 
The average patient age was 28. Clinical indices for (i) tic severity 
(Yale Global Tic Severity Score) and (ii) depression (Hamilton 
Depression rating Scale) and (iii) age were collected pre and post 
DBS. These clinical data were converted QALYs using standard-
ized coefficients derived from a multivariate regression published 
by Müller-Vahl et al (2010) for a sample 200 German outpatients 
(R 2 = 54%).
The direct costs for DBS, included hardware, surgical implan-
tation, inpatient stay, neurostimulator programming and adverse 
events. For BMT direct costs included estimates for rehabilitation, 
inpatient stay, outpatient treatment, pharmaceuticals and ancillary 
treatments. All costs were reported in $US2016. TreeAge® soft-
ware was used to estimate an Incremental Cost Effectiveness Ratio 
(ICER) using a Markov model, with a 10-year time horizon and 
3.5% discount rate. 
Results: The direct costs of DBS and BMT were estimated to 
be $USD 124,400 and $USD 34,180, respectively. DBS was esti-
mated to increase health utility from 0.45 to 0.78. The ICER of 
DBS was estimated to be $USD 27,600 per QALY gained, which 
is lower than the nominal US Food and Drug Administration 
(FDA) approved threshold of $USD 50,000 per QALY. 
Conclusions: Our initial exploration suggests DBS is a cost-
effective treatment for patients with severe TS. However, our eco-
nomic evaluation contains several limitations. Firstly, indirect 
costs were not included. Secondly, health utilities pre and post 
DBS were imputed from clinical data rather than measured direct-
ly. Thirdly, long-term costs and benefits are uncertain; an average 
age of 28 years at implant implies a further 50 years of life post 
DBS. The ICER was sensitive to estimates of adverse events. Fi-
nally, our results were derived from a small sample. Future re-
search will administer a survey of healthcare costs and QALYs to 
an international database of TS patients treated with DBS main-
tained by the University of Florida, with the aim of developing a 
more robust economic evaluation. 
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Introduction: STN DBS has been shown to drastically im-
prove motor symptoms of PD. However, the occurrence of dis-
abling side effects may limit the benefit of the therapy. Computed 
models have suggested that directional stimulation could increase 
its efficacy. Intraoperative studies performed in human have 
shown that directional stimulation provides differents thresholds 
for clinical effects. In the present study, we investigate the effect 
of directional stimulation on beneficial and side effects, in chron-
ically implanted patients compared to omnidirectional stimula-
tion.
Methods: 11 bilateral STN implanted PD patients have been 
prospectively included in this study. In the trajectory determined 
after microrecording and intraoperative clinical testing, the defin-
itive directional lead (1-3-3-1 electrode configuration, Vercise, 
Boston Scientific) was implantated with one electrode oriented 
medially, one anterolaterally and the third posterolaterally, under 
intraoperative fluoroscopic control. Monopolar omnidirectional 
stimulation was initially performed. 2–3 month after surgery, di-
rectional stimulation was assessed. The current threshold for ben-
eficial and side effects was assessed for each of the 3 directions 
and compared to omnidirectional stimulation.
Results: A best direction of stimulation was observed in all 
patients in terms of therapeutic window. The current required to 
obtain a beneficial effect in the best direction showed a mean re-
duction of 25% compared to the omni-directional condition. The 
current required to achieve a sustained side effect in the worst di-
rection was comparable to the in the omni-directional situation. 
The medially oriented directional electrode war found in 9/14 sides 
to have the highest threshold for side effects.
Conclusion: Our preliminary experience using Directional 
DBS in the STN performed postoperatively suggests the persis-
tence of different thresholds for the appearance of clinical effects 
in directional stimulation conditions, compared to omnidirectional 
stimulation. Further data are needed to confirm these observations.
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Objectives: The aim of this study was to evaluate the long-
term efficacy and safety of the constant current devices (Libra 
DBS System™) produced by St. Jude’s Medical in patients with 
essential tremor.
Design: The inclusion criteria required all the patients to have 
had a clinical diagnosis of essential tremor by a movement disorder 
neurologist, deemed suitable for DBS by a multi-disciplinary team 
consisting of a movement disorders neurologist, neuropsycholo-
gist, neuropsychiatrist, movement disorders neurosurgeon, and a 
deep brain stimulation (DBS) specialist nurse, and had a minimum 
of 3 years of constant current stimulation of the Vim DBS. Patients 
with other movement disorders were excluded.
Subject: Ventralis intermedius (Vim) DBS is an established 
intervention for medication-refractory essential tremor. Newer 
constant current DBS technology offers theoretical advantage 
over the traditional constant voltage systems in terms of deliver-
ing a more biologically stable therapy. There are no previous re-
ports on the outcomes of Vim constant current DBS in the treat-
ment of essential tremor. Here we report on the long-term effi-
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